Kymera Therapeutics KYMR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -697.7%+193pp | -891.1%-131pp | -759.7%-62.2pp | -697.5%-225pp | -472.5%+83.3pp | |
| Net margin | -612%+182pp | -794.1%-119pp | -674.8%-58.8pp | -616%-207pp | -409.1%+66.5pp | |
| EBITDA margin | -681.6%+188pp | -869.9%-129pp | -740.8%-61.4pp | -679.4%-220pp | -459%+81.2pp | |
| Free cash flow margin | -474%+124pp | -597.7%-71.3pp | -526.4%+39.3pp | -565.7%-158pp | -407.5%+33.0pp | |
| Returns | ||||||
| Return on equity | -27.1%-1.3pp | -25.8%+6.3pp | -32.1%+1.2pp | -33.3%-1.1pp | -32.2%+4.2pp | |
| Return on assets | -24.3%-1.5pp | -22.9%+4.7pp | -27.6%+0.5pp | -28.1%-1.2pp | -27%+1.8pp | |
| Return on invested capital | -31.8%+1.3pp | -33.1%+4.0pp | -37.1%+6.5pp | -43.6%-6.3pp | -37.3%+7.2pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.8×+0.3× | 10.5×+3.1× | 7.4×-0.9× | 8.3×-0.2× | 8.5×+1.0× | |
| Quick ratio | 10.8×+0.3× | 10.5×+3.1× | 7.4×-0.9× | 8.3×-0.2× | 8.5×+1.0× | |
| Cash ratio | 2.3×-2.0× | 4.3×+2.7× | 1.6×-2.3× | 3.8×+2.3× | 1.5×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $15.79-15.6% | $18.70+72.5% | $10.84-10.2% | $12.08+23.1% | $9.81-11.9% | |
| Valuation | ||||||
| Market capitalization | $6.8B+9.2% | $6.22B+53.8% | $4.05B+31.8% | $3.07B+72.7% | $1.78B-31.8% | |
| Enterprise value | $6.74B+13.2% | $5.95B+48.1% | $4.02B+42.5% | $2.82B+58.9% | $1.78B-31.0% | |
| Price / sales | 132.1×-26.7× | 158.8×+66.2× | 92.5×+23.9× | 68.7×+38.5× | 30.2×-25.2× | |
| Price / book | 4.4×+0.5× | 3.9×-0.3× | 4.3×+1.1× | 3.2×+0.9× | 2.3×-0.9× | |
| EV / sales | 130.9×-20.9× | 151.8×+59.9× | 91.9×+28.8× | 63.1×+33.0× | 30.2×-24.5× | |
| Free cash flow yield | -3.6%+0.2pp | -3.8%+1.9pp | -5.7%+2.6pp | -8.2%+5.3pp | -13.5%-5.5pp | |
| Earnings yield | -4.6%+0.4pp | -5%+2.3pp | -7.3%+1.7pp | -9%+4.6pp | -13.6%-5.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kymera Therapeutics's ratios come from?
- Every ratio is computed from Kymera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
